NASDAQ:SRDX
SurModics Stock News
$32.16
-0.160 (-0.495%)
At Close: May 10, 2024
SurModics (SRDX) Surges 6.1%: Is This an Indication of Further Gains?
09:02am, Tuesday, 24'th Jan 2023
SurModics (SRDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
Surmodics, Inc. (SRDX) Q4 2022 Earnings Call Transcript
08:45pm, Saturday, 12'th Nov 2022
Surmodics, Inc. (NASDAQ:SRDX ) Q4 2022 Earnings Conference Call November 9, 2022 10:00 AM ET Company Participants Gary Maharaj - CEO, President & Director Timothy Arens - SVP, Finance & Information Te
Surmodics (SRDX) Q4 Earnings and Revenues Top Estimates
09:47am, Thursday, 10'th Nov 2022
Surmodics (SRDX) reports a solid fiscal fourth quarter top line on the back of robust Medical Device revenues.
Surmodics to Report Fourth Quarter and Fiscal Year 2022 Financial Results on November 9th
07:30am, Friday, 28'th Oct 2022
EDEN PRAIRIE, Minn.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
12:47pm, Tuesday, 27'th Sep 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio Now
03:48pm, Wednesday, 24'th Aug 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View
02:27pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.
Surmodics, Inc. (SRDX) CEO Gary Maharaj on Q3 2022 Results - Earnings Call Transcript
03:36pm, Wednesday, 27'th Jul 2022
Surmodics, Inc. (NASDAQ:SRDX ) Q3 2022 Earnings Conference Call July 27, 2022 8:30 AM ET Company Participants Gary Maharaj - President and Chief Executive Officer Tim Arens - Senior Vice President of
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
12:55pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27
08:30am, Tuesday, 19'th Jul 2022
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- #Catheter--Surmodics to Webcast Third Quarter Fiscal 2022 Earnings Conference Call on July 27. Webcast is Live at 7:30 a.m. (CT)
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
03:34pm, Monday, 18'th Jul 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
01:09pm, Monday, 18'th Jul 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
02:52pm, Thursday, 16'th Jun 2022 Zacks Investment Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
12:20pm, Thursday, 16'th Jun 2022
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
